BDTX today
$1.61+$0.02 (+0.94%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourSymmetric Triangle
1 hourLeaning Bullish
15 minBullish
5 minDescending Triangle
Daily trend turns up above $2.32
Key levels
Resistance$1.90
Resistance$1.64
Support$1.46
Support$1.20
Latest news & SEC filings
NewsBlack Diamond Therapeutics Stock Soars on Tuesday
EarningsBlack Diamond Therapeutics gives Phase 2 silevertinib update, FDA feedback, Q3 2026 results
SEC FilingBlack Diamond Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All BDTX news →About Black Diamond Therapeutics
Black Diamond Therapeutics is a biopharmaceutical firm focused on creating drugs for tumors driven by specific genetic mutations. Its main candidate, silevertinib, is an oral EGFR inhibitor in mid-stage testing for lung cancer and glioblastoma. The company also has an FGFR2/3 program and licensed a RAF inhibitor to Servier. It is based in the United States.
Based on the company's 10-K filed Mar 16, 2026.
Nasdaq · Healthcare
Black Diamond Therapeutics, Inc. (BDTX)
What Is the Price Target for BDTX?
SEPT Low Target
$11.00
SEPT Mid Target
$11.00
SEPT High Target
$11.00
Analyst Consensus
$11.00
Is BDTX a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BDTX.
Start Free Trial →Is BDTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$9.32
33
Moat Score
NONE
7/9
Piotroski Score
-0.7
Altman Z-Score
What Is Smart Money Doing with BDTX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Behbahani Ali | director | Buy | 7,707 | $15K | Sep 18, 2026 |
| Raman Prakash | director | Buy | 6,801 | $13K | Sep 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BDTX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
130.71%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for BDTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BDTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:54:43 | $1.60 | 1,800 | $$3K | MIDPOINT |
| 20:52:32 | $1.61 | 2,115 | $$3K | BUY |
| 20:35:13 | $1.59 | 2,000 | $$3K | SELL |
| 20:34:28 | $1.59 | 1,333 | $$2K | SELL |
| 20:31:02 | $1.59 | 2,500 | $$4K | SELL |
5 dark pool trades shown · $$16K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Black Diamond Therapeutics, Inc. (BDTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BDTX — frequently asked questions
What is BDTX stock price today?
Black Diamond Therapeutics, Inc. (BDTX) is at $1.61, up 0.94% (+$0.02) at the Nov 11, 2026 close.
Why is BDTX stock moving today?
Latest BDTX news — Nov 10, 2026: Black Diamond Therapeutics Stock Soars on Tuesday · Nov 10, 2026: Black Diamond Therapeutics gives Phase 2 silevertinib update, FDA feedback, Q3 2026 results
What is the BDTX price target?
The average analyst price target for BDTX is $11.00, ranging from $11 to $11, based on 2 analysts.
What do analysts rate BDTX?
Analyst ratings for BDTX: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did BDTX beat earnings?
BDTX last reported on Aug 5, 2026: EPS -$0.17 vs -$0.20 expected — a beat of 13.0%.
Does BDTX pay a dividend?
BDTX does not currently pay a dividend.
What are BDTX support and resistance levels?
Support: $1.46, $1.20. Resistance: $1.64, $1.90, $2.14.
What are insiders doing with BDTX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on BDTX?
Nov 10, 2026: Black Diamond Therapeutics Stock Soars on Tuesday · Nov 10, 2026: Black Diamond Therapeutics gives Phase 2 silevertinib update, FDA feedback, Q3 2026 results · Nov 10, 2026: Black Diamond Therapeutics, Inc. filed a report on a major company event (Form 8-K)